This project deals with the interactions between EBV-infected cells and the host immune system in normal and immunodefective persons. For an improved understanding of this complex system, it is necessary to broaden our knowledge both on the interaction of the virus with different host cells in vitro and in vivo, and on the interplay between the virally infected cells and the host. This project aims at the analysis of certain questions at both levels, in a mutually interrelated way. The project consists of the following parts: I. Analysis of the virus-cell-host system II. Clinically related studies Antigenic analysis will focus on the role of the newly detected membrane antigen on the surface of transformed, proliferating, non-virus producer cells, its immune recognition, its genetic determination mechanism (in relation to the viral genome) and the significance of blocking antibodies directed against it. Effector analysis will disssect the role of various lymphocyte subtypes and mediators in BL and NPC, immunodefectives with and without EBV-carrying lymphoproliferative disease, and in healthy controls. At the target cell level, continued attention will be given to the role of spontaneous or induced B-cell differentiation by immunological and non-immunological host control. The clinically related studies wil focus on the monoclonal vs. polyclonal nature of EBV-transformed B-cell proliferation in transplant lymphomas, and lymphoproliferative disease in XLP, as it relates to EBV. At the effector level, we shall continue to investigate the impairment of different effectors and the role of suppression in immunodeficient EBV-carrying lymphomas, as contrasted to immunodefective states (HD and NHL, AT) with an impaired control of EBV-transformed cells (as indicated by the dissociation of sensitization and antibody formation into EBNA, on the one hand, and to EA/VCA on the other), but without EBV carryig lymphoproliferative disease. A special effector and target cell study will be carried out on pre-AIDS lymphomas.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA030264-04
Application #
3169159
Study Section
Experimental Immunology Study Section (EI)
Project Start
1981-09-01
Project End
1988-02-29
Budget Start
1985-03-01
Budget End
1986-02-28
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Karolinska Institute
Department
Type
DUNS #
350582235
City
Stockholm
State
Country
Sweden
Zip Code
171 77
Contreras-Brodin, B; Karlsson, A; Nilsson, T et al. (1996) B cell-specific activation of the Epstein-Barr virus-encoded C promoter compared with the wide-range activation of the W promoter. J Gen Virol 77 ( Pt 6):1159-62
Chen, F; Hu, L F; Ernberg, I et al. (1995) Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas. J Gen Virol 76 ( Pt 1):131-8
Stuber, G; Dillner, J; Modrow, S et al. (1995) HLA-A0201 and HLA-B7 binding peptides in the EBV-encoded EBNA-1, EBNA-2 and BZLF-1 proteins detected in the MHC class I stabilization assay. Low proportion of binding motifs for several HLA class I alleles in EBNA-1. Int Immunol 7:653-63
Lewin, N; Avila-Carino, J; Minarovits, J et al. (1995) Detection of two Epstein-Barr-virus (EBV)-carrying leukemic cell clones in a patient with chronic lymphocytic leukemia (CLL). Int J Cancer 61:159-64
Hu, L F; Chen, F; Zhen, Q F et al. (1995) Differences in the growth pattern and clinical course of EBV-LMP1 expressing and non-expressing nasopharyngeal carcinomas. Eur J Cancer 31A:658-60
Trivedi, P; Zhang, Q J; Chen, F et al. (1995) Parallel existence of Epstein-Barr virus (EBV) positive and negative cells in a sporadic case of Burkitt lymphoma. Oncogene 11:505-10
Chen, F; Zou, J Z; di Renzo, L et al. (1995) A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 69:3752-8
Zheng, X; Hu, L; Chen, F et al. (1994) Expression of Ki67 antigen, epidermal growth factor receptor and Epstein-Barr virus-encoded latent membrane protein (LMP1) in nasopharyngeal carcinoma. Eur J Cancer B Oral Oncol 30B:290-5
Moss, D J; Burrows, S R; Suhrbier, A et al. (1994) Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response. Ciba Found Symp 187:4-13;discussion 13-20
de Campos-Lima, P O; Levitsky, V; Brooks, J et al. (1994) T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med 179:1297-305

Showing the most recent 10 out of 87 publications